Nuvalent, Inc.
NUVL$3.60B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
6
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
NUVL News
Catalyst Timeline
6 upcoming, 0 past
Drug Pipeline
Neladalkib (NVL-655)
Non-small Cell Lung Cancer
Zidesamtinib (NVL-520)
Locally Advanced Solid Tumor
Midazolam
Locally Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Neladalkib (NVL-655) | Phase 3 | Non-small Cell Lung Cancer | - | - |
Zidesamtinib (NVL-520) | Phase 2 | Locally Advanced Solid Tumor | - | - |
Midazolam | Phase 2 | Locally Advanced Solid Tumor | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply